Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

Study Overview

This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma.

The drugs involved in this study are:

  • Pembrolizumab (Keytruda)
  • Trametinib (Mekinist)
  • Dabrafenib (Tafinlar)

Study Description

A phase II trial of abbreviated MAPK targeted therapy plus pembrolizumab in patients with unresectable or metastatic melanoma

  • ClinicalTrials.gov Identifier: NCT03149029
  • Protocol Number: 16-642

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000